Rockwell Medical Q2: Sales Fall 38% After DaVita Exit; IRC Deal and ATM Backstop

Rockwell Medical, Inc. (NASDAQ: RMTI) - Q2 2025 snapshot

Quick take
* Revenue is sliding sharply after losing material volume from a major customer (DaVita).
* Management says liquidity is sufficient for at least 12 months, but the company still depends on access to capital (ATM facility) and execution of commercial plans.
* Operational focus: cost containment, new customer wins (recent IRC agreement) and running three U.S. manufacturing sites.

Income statement - positives
* Gross margin held at ~16% for the six months ended June 30, 2025 (Gross Profit $5,545 vs $7,614 in 6M 2024).
* Interest income and realized investment gains provided a small offset to interest expense (Other, six months: (298)).
* Non-recurring/one-time supports from DaVita: quarterly non‑refundable payments totaling $1.3M recognized in 6M 2025 to support supply continuity.

Income statement - negatives
* Sales decline: Q2 net sales $16,071 vs Q2 2024 $25,832 (down 38% Q/Q year-over-year); 6M sales $34,985 vs $48,508 (down 28%).
* Net loss: Q2 (1,492); 6M (3,007). Basic EPS: Q2 $(0.05); 6M $(0.09).
* Cost of sales remains high in absolute terms: Q2 cost of sales $13,568; gross profit fell to $2,503 in Q2.
* Major revenue concentration shift: DaVita sales fell materially (Q2 decrease ~$9.9M; 6M decrease ~$14.6M) as DaVita transitions to another supplier - creates near-term revenue pressure.

Key balance sheet & cashflow stats (as reported)
* Cash and cash equivalents: $12,482 (thousands). Investments available-for-sale: $5,940 - total cash + investments ≈ $18.4 million.
* Total current assets: $31,609; Total assets: $52,625.
* Total current liabilities: $10,946; Total liabilities: $22,216.
* Stockholders' equity: $30,409.
* Net working capital: ~$20.7 million (management disclosure).
* Term Loan (net): $8,648 (long‑term, net of issuance costs). Total debt maturities schedule shows principal due starting 2027 ($3,814) and final maturity Jan 1, 2029 (includes Final Fee).
* Deferred consideration - current: $2,500.
* Accounts receivable, net: $8,084; Inventory, net: $4,160 (current).
* Operating cash flow (6M): Net cash used in operating activities $(1,643). Investing net $(104); Financing net $(1,433).
* Shares outstanding (Aug 6, 2025): 34,430,352; weighted avg basic shares in Q2: 34,311,306.

What's happening inside the company - operational & strategic points
* Manufacturing footprint intact: three facilities in Michigan, South Carolina and Texas; dry acid mixers in Iowa - company continues fulfillment operations.
* Customer mix shifting: DaVita went from ~45% of Q2 2024 sales to 11% of Q2 2025 sales (for the quarter) and 20% for the six months - major loss of concentration but some recovery via new customers and pricing.
* New customer win: a multi‑million dollar supply agreement with Innovative Renal Care (IRC) with utilization commitments for three years (option to extend one year) - a near-term commercial offset/catalyst.
* Cost management: management implemented cost containment and paused R&D on Triferic; wrote off international Triferic inventory ($0.2M write-off recorded in cost of sales).
* Compensation & incentives: notable equity programs - service-based RSU grants (1,000,000 granted YTD) and 717,000 market-condition RSUs granted in Q2; stock‑based compensation expense increased (6M $827). These are dilution/cost and retention tools.

Near-term risks & catalysts - what to watch
* DaVita contract outcome and volumes - continued supply, extension, or replacement volumes are critical to revenue recovery.
* Execution of the IRC agreement and ramp timing - whether utilization commitments convert to cash flow as expected.
* Liquidity actions: use of ATM facility (≈$21.1M available) or other financing - potential dilution and covenant implications (DaVita SPA limits certain financings until holdings change).
* Covenant monitoring on the Innovatus Term Loan - company remediated revenue covenant via updated projections; future performance will be monitored by lender.
* Cash burn and working capital trends - operating cash use was $(1,643) for 6M; management says current funds and expected operations cover at least next 12 months but additional capital may be required.

Bottom line (straightforward)
* Rockwell Medical (NASDAQ: RMTI) is experiencing a meaningful revenue decline driven by a customer transition (DaVita). Management has taken cost and commercial actions (new IRC deal, cost containment) and has ~$18.4M in cash + investments and an ATM backstop (~$21.1M available).
* The company remains operationally solid (manufacturing, certifications, and delivery), but the near-term financial story hinges on converting new customer volume, preserving margins, and accessing capital on acceptable terms if needed. Continued monitoring of revenue recovery, covenant compliance, and cash runway is essential.